에 대한 최신 뉴스 Hoth Therapeutics (NASDAQ:HOTH) 주식

Hoth Therapeutics

Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.

Hoth Therapeutics Inc

Wells Fargo analyst Joseph O'Dea maintains Acuity Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AYI#NYSE">AYI</a>) with a Equal-Weight and raises the price target from $320 to $336.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Acuity Brands, Raises Price Target to $336

Royal Bank Of Canada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RY#NYSE">RY</a>) disclosed its partnership with Cohere to co-develop a generative AI solution<a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42893498/rbc-and-cohere-partner-to-develop-the-next-generation-of-highly-secure-generative-ai-solutions-for" rel="noreferrer noopener"> tailored for financial services</a>.
Cohere is a security and privacy-focused enterprise AI. The companies aim to create a secure generative AI platform called North for Banking.
North for Banking will integrate with both RBC&#8217;s and Cohere&#8217;s proprietary models, as well as RBC&#8217;s internal platforms.
The solution will use both companies&#8217; AI models and RBC&#8217;s internal systems to speed up AI development, focusing on improving security and risk management for the financial sector.
Cohere co-founder Ivan Zhang stated that North for Banking is a complete AI solution designed to help financial firms boost productivity and efficiency. With a strong focus on security and data privacy, companies can confidently adopt the platform on a large scale.
Royal Bank of&nbsp;Canada plans to host an Investor Day on&nbsp;Thursday, March 27, 2025, with presentations given by&nbsp;CEO Dave McKay and other management team members.
Investors can gain exposure to the stock via ETF Opportunities Trust Brendan Wood TopGun Index ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BWTG#BATS">BWTG</a>).
Price Action: RY shares closed higher by 0.28% at $121.67 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42823979/canadas-pm-justin-trudeau-steps-down-amid-internal-conflict-and-tension-over-trump-tariffs" target="_blank" rel="noreferrer noopener">Justin Trudeau Will Step Down As Canada Faces Tension Over Trump Tariffs</a></li>
</ul>
Photo via Shutterstock.

Equities

Large Cap

BWTG

RBC Teams Up with Cohere For GenAI Financial Solutions: Details

AutoZone's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) short percent of float has risen 21.86% since its last report. The company recently reported that it has 333 thousand shares sold short, which is 2.23% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>AutoZone Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736438422_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AutoZone has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing AutoZone's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AutoZone's peer group average for short interest as a percentage of float is 9.83%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About AutoZone?

Burlington Stores's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) short percent of float has risen 23.61% since its last report. The company recently reported that it has 2.30 million shares sold short, which is 4.66% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.77 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Burlington Stores Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736438416_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Burlington Stores has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Burlington Stores's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Burlington Stores's peer group average for short interest as a percentage of float is 12.74%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

BURL

How Is The Market Feeling About Burlington Stores?

Biogen's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NYSE">BIIB</a>) short percent of float has fallen 5.21% since its last report. The company recently reported that it has 2.58 million shares sold short, which is 2.0% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.94 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Biogen Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736438411_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Biogen has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Biogen's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Biogen's peer group average for short interest as a percentage of float is 5.09%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

BIIB

Peering Into Biogen's Recent Short Interest

Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) has outperformed the market over the past 20 years by 1.43% on an annualized basis producing an average annual return of 9.73%. Currently, Charles Schwab has a market capitalization of $133.81 billion. 
Buying $1000 In SCHW: If an investor had bought $1000 of SCHW stock 20 years ago, it would be worth $6,409.13 today based on a price of $73.10 for SCHW at the time of writing.
<h3>Charles Schwab's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736438409_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SCHW

Here's How Much You Would Have Made Owning Charles Schwab Stock In The Last 20 Years

Cantor Fitzgerald analyst Jonathan Ruykhaver initiates coverage on SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) with a Overweight rating and announces Price Target of $30.

Initiation

Cantor Fitzgerald Initiates Coverage On SentinelOne with Overweight Rating, Announces Price Target of $30

On Thursday, Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) released results from the IRAKLIA phase 3 study evaluating the non-inferiority of Sarclisa (isatuximab) subcutaneous formulation via an on-body delivery system (OBDS) versus weight-based dosed Sarclisa IV in combination with pomalidomide and dexamethasone (Pd) in adult patients with relapsed or <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39169252/sanofi-highlights-data-from-blood-cancer-drug-sarclisa-in-new-diagnosed-multiple-myeloma-patients" rel="noreferrer noopener">refractory multiple myeloma</a>.&nbsp;
The <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-01-09-06-00-00-3006798" rel="noreferrer noopener">trial</a> demonstrated that Sarclisa SC, in combination with pomalidomide and dexamethasone (Pd), met its co-primary endpoints of non-inferior objective response rate and observed concentration before dosing (C trough) at steady state.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42530062/sanofis-340b-credit-proposal-draws-federal-warning-for-statutory-violation" rel="noreferrer noopener">Sanofi&#8217;s 340B Credit Proposal Draws Federal Warning For Statutory Violation</a>
Key secondary endpoints were also achieved, including very good partial response, the incidence rate of infusion reactions, and C trough at cycle 2.
The study is ongoing, and the full results will be presented at a forthcoming medical meeting.
Additional studies evaluating Sarclisa SC formulations across different combinations and lines of therapy are ongoing.
The safety and efficacy of Sarclisa SC and the enFuse device have not been evaluated by any regulatory authority outside of their approved indications. Regulatory submissions in the US and in the EU are planned during the first half of 2025.
In September, the FDA approved&nbsp;Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option for adult patients with newly diagnosed multiple myeloma who are not eligible for autologous <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40979253/sanofis-sarclisa-secures-fda-approval-for-first-line-multiple-myeloma-marking-its-third-us-approv" rel="noreferrer noopener">stem cell transplant</a>.
In August, Sanofi released new results from the GMMG-HD7 phase 3 study of Sarclisa in combination with lenalidomide, bortezomib, and dexamethasone (RVd) versus RVd induction followed by post-transplant re-randomization to Sarclisa plus lenalidomide versus lenalidomide maintenance in transplant-eligible newly diagnosed <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40260365/sanofis-approved-blood-cancer-drug-sarclisa-shows-improved-progression-free-survival-in-patients-" rel="noreferrer noopener">multiple myeloma patients</a>.
The data&nbsp;show&nbsp;that Sarclisa, combined with RVd during induction therapy, significantly prolonged progression-free survival, resulting in a statistically significant and clinically meaningful reduction in disease progression or death compared to RVd induction regardless of the maintenance regimen.
Price Action: SNY stock closed at $49.23 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42896803/medicare-to-cover-eli-lillys-weight-loss-drug-zepbound-for-obstructive-sleep-apnea-treatment" target="_blank" rel="noreferrer noopener">Medicare To Cover Eli Lilly&#8217;s Weight Loss Drug Zepbound For Obstructive Sleep Apnea Treatment</a></li>
</ul>
Image by HJBC via Shutterstock

Biotech

Health Care

General

Sanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma

Cantor Fitzgerald analyst Jonathan Ruykhaver initiates coverage on Check Point Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) with a Neutral rating and announces Price Target of $200.

CHKP

Cantor Fitzgerald Initiates Coverage On Check Point Software with Neutral Rating, Announces Price Target of $200

Cantor Fitzgerald analyst Jonathan Ruykhaver initiates coverage on Varonis Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) with a Overweight rating and announces Price Target of $60.

VRNS

Cantor Fitzgerald Initiates Coverage On Varonis Systems with Overweight Rating, Announces Price Target of $60

JMP Securities analyst Patrick Walravens downgrades Paycor HCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>) from Market Outperform to Market Perform.

Downgrades

PYCR

JMP Securities Downgrades Paycor HCM to Market Perform

Keybanc analyst Noah Zatzkin maintains YETI Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YETI#NYSE">YETI</a>) with a Underweight and lowers the price target from $36 to $35.

YETI

Keybanc Maintains Underweight on YETI Holdings, Lowers Price Target to $35

Raising children with good values is a challenge for any parent, but it gets even trickier when you're among the <a href="https://www.benzinga.com/startups/25/01/42805604/a-2m-bet-on-recovery-bill-gates-quietly-buys-2-stocks-he-believes-will-define-2025s-economic-boom">richest people in the world</a>.&nbsp;
Bill and Melinda Gates, despite their multi-billion-dollar net worth, made headlines for their decision to <a href="https://www.benzinga.com/markets/25/01/42802980/bill-gates-is-so-frugal-he-wears-a-10-watch-but-spent-42000-in-fines-for-manure-bins-at-his-daughters-8-7-million-florida-horse-farm">raise their three children – </a>Jennifer, Rory and Phoebe – with what they describe as a "middle-class" upbringing. It wasn't about downplaying their wealth but about instilling a sense of responsibility, empathy and independence.
In a July 2024 interview with The New York Times, Melinda Gates explained, "I think it was much more of an upbringing like I grew up in – a very middle-class household where money dictated whether I got an extra pair of shoes each year or not. I thought that was a good principle to have."
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
</ul>
Middle-Class Values in an Extraordinary World
So, <a href="https://www.benzinga.com/personal-finance/24/09/41102547/is-your-income-higher-than-the-average-middle-class-household-heres-what-theyre-earning">what does "middle-class" mean</a> when your parents are global philanthropists? For the Gates children, it meant allowances, chores and even discretion about their lifestyle.
"We said to them from a very early age, ‘You're really not allowed to tell other people how we flew on this trip back and forth. Otherwise, it will separate you from other children,'" Melinda said. The aim wasn't to deny their wealth but to ensure their kids didn't grow up feeling entitled or detached from reality.
According to the Independent, Bill Gates echoed this sentiment, emphasizing that their goal was to "strike a balance where they have the freedom to do anything, but not a lot of money showered on them so they could go out and do nothing."
See Also: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a>
Key Lessons from the Gates Family Playbook
Here are some of the standout ways the Gates family tried to ground their children:
1. Allowances, Not Handouts
The Gates kids received allowances and had to budget their money carefully. They weren't handed everything on a silver platter. They had to spend their allowance or add it to a wish list for birthdays or holidays if they wanted something.
2. Charity Begins at Home
At least one-third of their allowance was set aside for <a href="https://www.benzinga.com/general/social-media/24/12/42677188/elon-musk-calls-jeff-bezos-ex-wife-mackenzie-scotts-19-billion-charitable-donations-concerning">charitable giving – </a>a rule their parents matched. This wasn't just about writing checks but about teaching empathy and the importance of giving back.
3. Earning Through Chores
Like many families, the Gates had household chores. This wasn't a symbolic gesture but a way of fostering accountability and work ethic.
4. No Phones Until 14
While the average teen might not think of a smartphone as a "luxury," the Gateses did. Their kids weren't allowed phones until they turned 14, emphasizing delayed gratification and technological boundaries.
5. No Name-Dropping – Literally
Melinda revealed that the couple avoided putting their names on university buildings to prevent their kids from feeling overshadowed. "Universities come to us and if we do a large gift … they want us to put our name on a building. I don't think that's a good idea because for our children … they don't want to sit in a building that has their parents' name on it," she explained.
Trending: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
Grounding Kids in Reality, No Matter the Tax Bracket
The irony of calling their approach "middle-class" isn't lost on anyone. After all, most middle-class families aren't grappling with how to explain private jets to their kids. But the lessons <a href="https://www.benzinga.com/personal-finance/24/11/41809171/bill-gates-says-being-a-billionaire-is-overrated-being-rich-brings-you-freedom-but-beyond-that-i">Bill and Melinda Gates aimed to teach – </a>financial responsibility, humility and self-reliance – are universally relevant.
The Gates' parenting philosophy reminds us that wealth alone doesn't define a person's character. Whether you're a billionaire or living paycheck to paycheck, the values you pass on to your children matter.
As Melinda put it, "I went to school with some of those kids at Duke University and I vowed to myself that if I ever had resources at my disposal, those were not the kind of children I wanted to raise."
Conversations about money, work ethic and giving back don't require billions – they just require intention. For families navigating their financial values and goals, <a href="https://www.benzinga.com/money/are-you-rich">consulting a financial advisor</a> can be a great way to create a clear plan. Whether you're teaching kids about budgeting or planning for generational wealth, having expert guidance ensures your intentions translate into actionable steps.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/advisor-adv-warren-buffett">Warren Buffett Flipped His Neighbor's $67,000 Life Savings Into A $50 Million Fortune — This Would Be Worth Over $500 Million Today</a></li>
</ul>

Personal Finance

Bill And Melinda Gates Say They Raised Their 3 Daughters With A 'Middle-Class' Upbringing–'You're Not Allowed to Tell People How We Flew …'

EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) has outperformed the market over the past 15 years by 10.75% on an annualized basis producing an average annual return of 22.35%. Currently, EQT has a market capitalization of $29.24 billion. 
Buying $1000 In EQT: If an investor had bought $1000 of EQT stock 15 years ago, it would be worth $20,274.09 today based on a price of $49.00 for EQT at the time of writing.
<h3>EQT's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736437508_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

RBC Capital analyst Scott Hanold reiterates Tamboran Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBN#NYSE">TBN</a>) with a Sector Perform and maintains $31 price target.

Reiteration

RBC Capital Reiterates Sector Perform on Tamboran Resources, Maintains $31 Price Target

Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) said on Thursday that it is significantly expanding its wellness offerings, with plans to introduce over 2,000 new items across a variety of categories, including <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42893497/target-is-expanding-its-wellness-assortment-with-2-000-new-items-more-than-half-under-10" rel="noreferrer noopener">more than 600 exclusive products.</a>
This expansion reflects Target&#8217;s strategy&nbsp;of making wellness products more accessible and affordable, with over half of the new items priced under $10, the company said in a press release.
The company&#8217;s integrated approach spans multiple areas of wellness, from beauty and personal care to nutrition, food, and wellness technology, ensuring that consumers can curate a personalized wellness regimen.
Target&#8217;s new assortment includes emerging brands and exclusive partnerships.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/01/42894683/los-angeles-wildfires-stoke-investor-fears-edison-internationals-stock-ended-10-lower-on-wednesday-amid-concerns-over-possible-equipment-links-to-forest-fires" rel="noreferrer noopener">Los Angeles Wildfires Stoke Investor Fears: Edison International&#8217;s Stock Ended 10% Lower On Wednesday Amid Concerns Over Possible Equipment Links To Forest Fires</a>
In the beverage category, the retailer is introducing non-alcoholic beverages like BERO, a premium beer co-founded by actor Tom Holland. Target is also expanding its beauty and self-care offerings, with new haircare lines from Ashley Tisdale&#8216;s Being Frenshe and Blake Lively&#8216;s Blake Brown, as well as wellness gummies from Kourtney Kardashian Barker&#8216;s Lemme brand.
Additionally, Target is enhancing its men&#8217;s wellness selection with products from Dr. Squatch and Dwayne &#8220;The Rock&#8221; Johnson&#8216;s Papatui line, along with expanding its wellness technology category, introducing innovative items like SLF&#8217;s infrared red light therapy mask and Therabody&#8217;s SmartGoggles.
Target is also adding new activewear, loungewear, and sleepwear options to cater to growing wellness and self-care trends. The expanded wellness range will be available in 2025, allowing consumers to support their well-being while staying within their budget.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, TGT stock has lost over 3% in the past year. Investors can gain exposure to the stock via&nbsp;VanEck Retail ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTH#NASDAQ">RTH</a>).
Price Action: TGT shares closed lower by 0.74% to $138.22 on Wednesday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/42890191/trump-themed-nfts-launch-on-bitcoin-network-for-first-timeheres-what-you-should-know" target="_blank" rel="noreferrer noopener">Trump-Themed NFTs Debut On Bitcoin Network — One Card Gets Listed At $1.9 Million</a></li>
</ul>
Photo courtesy: Shutterstock.

Markets

Merrill Lynch Retail HOLDRS Trust due 12/31/41

Target's Wellness Push: Over 50% Of New Items Priced Under $10

RBC Capital analyst Ashish Sabadra reiterates Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Outperform and maintains $95 price target.

NDAQ

RBC Capital Reiterates Outperform on Nasdaq, Maintains $95 Price Target

Scotiabank analyst Orest Wowkodaw maintains Ivanhoe Mines (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IVN#TSX">IVN</a>) with a Sector Outperform and lowers the price target from C$21 to C$20.

TSX:IVN

Scotiabank Maintains Sector Outperform on Ivanhoe Mines, Lowers Price Target to C$20

The Federal Reserve indicated a more tempered approach to <a href="https://www.benzinga.com/25/01/42886101/investors-should-expect-no-rate-cuts-in-q1-2025-after-federal-reserves-december-minutes-release-strategist-says">interest rate cuts in 2025</a>.
That&#8217;s according to minutes from the Fed&#8217;s December meeting, which were released on Wednesday, Jan. 8. 
Investor interest shifted toward treasury bonds, as the 10-year yield briefly touched 4.73% on Wednesday, amid resurfacing inflation fears and anticipation around potential tariffs and tax policies. 
Fixed-income exchange-traded funds (ETFs) can help investors get exposure to bonds. This is thanks to the stability and predictable income opportunity amid equity market volatility that they hold.
Here are three standout ETFs poised to benefit:
<ul>
<li>iShares iBoxx $ Investment Grade Corporate Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LQD#NYSE">LQD</a>) offers diversified exposure to investment-grade corporate bonds, which are less likely to default during economic uncertainty. The ETF boasts a weighted average maturity of 12.94 years but includes bonds with varying maturities to balance risk. Its 30-day SEC yield is 5.4%, and its expense ratio is 0.14%, making it a cost-effective option.</li>
</ul>
<ul>
<li>Vanguard Short-Term Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSV#NYSE">BSV</a>) is designed for stability and focuses on short-duration U.S. Treasury and investment-grade corporate bonds, with an average maturity of just 2.8 years. Music to the ears for risk-averse investors looking to shield themselves from rate volatility. The fund&#8217;s 30-day SEC yield is approximately 4.4%, with minimal sensitivity to interest rate changes. A low expense ratio of 0.04% makes it even more attractive.</li>
</ul>
<ul>
<li>Vanguard Total Bond Market ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BND#NASDAQ">BND</a>) offers comprehensive exposure to the entire U.S. bond market, including Treasuries, mortgage-backed securities, and investment-grade corporate bonds. The ETF's 30-day SEC yield stands at 4.55%, providing a steady income stream. An expense ratio of 0.03% is another point to note. Additionally, the ETF's liquidity and resilience during past crises, such as the 2020 pandemic sell-off, makes it a reliable long-term investment choice.</li>
</ul>
<h3 class="wp-block-heading">Why Bond Funds?</h3>
The Fed's cautious message supports a longer-term case for bond ETFs. 
Short-duration bond ETFs are less sensitive to rate fluctuations and can offer better returns than cash or savings accounts while limiting interest rate risk.
Similarly, investment-grade corporate bond ETFs are a sweet spot for yield-seeking investors. These ETFs balance risk and reward by offering exposure to highly rated corporate debt that typically performs well in uncertain economic conditions.
These apart, ultra-short bond ETFs like the iShares 0-3 Month Treasury Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGOV#NYSE">SGOV</a>) could also gain traction as cash alternatives.
See Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/01/42895976/china-focused-etfs-face-uncertainty-as-us-blacklists-tencent-catl">China-Focused ETFs Face Uncertainty As US Blacklists Tencent, CATL</a></li>
</ul>
Photo via Shutterstock

Specialty ETFs

ETFs

SGOV

Fed's Cautious Rate Cut Approach Boosts Appeal Of These 3 ETFs

Osisko Gold Royalties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OR#NYSE">OR</a>) has outperformed the market over the past 5 years by 2.49% on an annualized basis producing an average annual return of 14.97%. Currently, Osisko Gold Royalties has a market capitalization of $3.47 billion. 
Buying $100 In OR: If an investor had bought $100 of OR stock 5 years ago, it would be worth $203.50 today based on a price of $18.60 for OR at the time of writing.
<h3>Osisko Gold Royalties's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736436616_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Osisko Gold Royalties 5 Years Ago Would Be Worth This Much Today

The MicroStrategy Effect: Reshaping Corporate Treasury Management

Hoth Therapeutics (HOTH) announced that it has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs. Thi...

Hoth Therapeutics partners with Dept. of Veterans Affairs on obesity treatment

Hoth licenses patents to develop anti-obesity treatments

Hoth Therapeutics (HOTH) shared encouraging interim safety and efficacy results from its Phase 2a clinical trial of HT-001, designed to address ski...

Hoth Therapeutics reports 'encouraging' results from Phase 2a trial of HT-001

After Hoth Therapeutics (HOTH) announced interim results from its Phase 2a CLEER-001 trial evaluating HT-001, a treatment for skin toxicities cause...

D. Boral says Hoth findings highlight HT-001 potential to 'revolutionize' care

13:29 EST Hoth Therapeutics (HOTH): Enrollment in HT-001 trial proceeding as planned Published first on TheFly – the ultimate source for real-time,...

Hoth Therapeutics: Enrollment in HT-001 trial proceeding as planned

13:28 EST Hoth Therapeutics (HOTH) affirms no plans for public, private offering at this time Published first on TheFly – the ultimate source for r...

Hoth Therapeutics affirms no plans for public, private offering at this time

Hoth Therapeutics (HOTH) responded to recent market rumors and inquiries from shareholders regarding its financial plans and ongoing clinical trial...

Hoth Therapeutics responds to market rumors, says no plans for offering

13:28 EST Hoth Therapeutics (HOTH): Strong balance sheet includes over $10M cash, no debt Published first on TheFly – the ultimate source for real-...

Hoth Therapeutics: Strong balance sheet includes over $10M cash, no debt

Hoth Therapeutics, XTI Aerospace, and Immuneering are the 3&nbsp;Penny Stocks&nbsp;to watch on January 9, 2025, based on&nbsp;TipRanks' Penny Stock...

3 Penny Stocks to Watch Now, 1/9/25

ACXP

HOTH

IMRX

MSTR

RUMBW

XTIA

Press Releases

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

Comments

Hoth Therapeutics

뉴스

에 대한 최신 뉴스 Hoth Therapeutics (NASDAQ:HOTH) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌